Dupilumab Reduces Exacerbations And Improves Lung Function Regardless Of Prior Asthma Exacerbation Status: LIBERTY ASTHMA TRAVERSE Open-Label Extension Study

Prior asthma exacerbations have been associated with lung function decline and increased risk of future exacerbations. Dupilumab, a human monoclonal antibody, blocks IL-4/IL-13, key central drivers of type 2 inflammation. We investigated the relationship between prior exacerbations and lung function in patients with moderate-to-severe type 2 asthma (blood eosinophils ≥150cells/μL or FeNO ≥25ppb at parent study baseline [PSBL]) from QUEST (NCT02414854) who enrolled in TRAVERSE (NCT02134028).